Form 4: Nurix Therapeutics' Chief Legal Officer, Christine Ring, Executes Stock Option and Sells Shares

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on October 1, 2024, according to a recent SEC filing.

Summary

• On October 1, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, exercised stock options to acquire 5,760 shares of common stock at a price of $1.86 per share.
• Simultaneously, Ring sold 5,760 shares of common stock in the open market.
• The sales were executed in multiple transactions with weighted average prices of $22.1931 and $22.81.
• Following these transactions, Ring directly owns 24,592 shares of Nurix Therapeutics common stock and holds options for 71,266 shares.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company executives. It is common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased trading volume.
• The filing provides transparency to stakeholders regarding insider transactions.

Key Dates